Analysis of Surgical Site Infection after Musculoskeletal Tumor Surgery: Risk Assessment Using a New Scoring System

Table 3

Case-specific data of SSI patients of malignant musculoskeletal tumors.

	Age/sex	Diagnosis	Site	Surgical procedure	Reconstruction	Duration of surgery (min)	Blood loss (g)	Isolated bacteria from SSI	Treatment for SSI	Oncological outcome/SSI healing	Treatment duration for SSI (month)
1	62/F	Metastatic bone tumor	Sacrum	Marginal resection	Artificial mesh	355	978	MRSA	Antibiotics, HBOT, surgery	DOD/not healed	18
2	61/M	Chondrosarcoma	Femur	Wide resection	Pasteurized autograft, plate and screw	383	500	CNS	Antibiotics, HBOT, surgery	CDF/healed	12
3	62/M	Metastatic bone tumor (thyroid)	Humerus	Marginal resection	Tumor-prosthesis	397	270	MSSA	Antibiotics, HBOT, surgery	DOD/healed	5
4	13/M	Osteosarcoma	Tibia	Wide resection	Tumor-prosthesis; Gastrocnemius muscle flap	445	470	MRSA	Antibiotics, HBOT, surgery	CDF/healed	9
5	35/M	Osteosarcoma	Pelvis	Hemipelvectomy	Liquid-nitrogen treated autograft, plate and screw, external fixator	890	4090	CNS	Antibiotics, HBOT, surgery	DOD/not healed	12
6	61/M	Metastatic bone tumor (kidney)	Femur	Wide resection	Tumor-prosthesis, Sartorius muscle flap	514	600	MSSA	Antibiotics, surgery (amputation)	AWD/healed	1
7	45/M	Myxoid liposarcoma	Thigh	Wide resection including Femur	Pasteurized autograft, plate and screw	680	1620	MRSA	Antibiotics, HBOT, surgery	DOD/not healed	18
8	79/F	MFH	Buttock	Wide resection	Gluteal artery perforator flap	145	50	MRSA	Antibiotics, HBOT	DOO/not healed	9
9	64/M	MFH	Thigh	Marginal resection	None	508	2505	Pseudomonas aeruginosa	Antibiotics, HBOT, surgery	DOD/not healed	9
10	82/M	Dedifferentiated liposarcoma	Thigh	Disarticulation of hip	None	391	220	Enterobacter cloacae	Antibiotics, surgery	CDF/healed	5
11	45/M	Myxoid liposarcoma	Thigh	Wide resection including Femur	Pasteurized autograft, plate and screw	550	470	CNS	Antibiotics, HBOT, surgery	CDF/healed	18
12	75/M	MFH	Lower leg	Wide resection including Tibia	Bone cement, intramedullary nail, Gastrocnemius muscle flap, FTSG	283	255	CNS	Antibiotics, HBOT, surgery (local flap)	CDF/not healed	21
13	30/M	MFH	Groin	Wide resection	None	250	105	Pseudomonas aeruginosa	Antibiotics, HBOT, surgery (rectus abdominis muscle flap)	CDF/not healed	3
14	70/F	MFH	Thigh	Marginal resection	Gastrocnemius muscle flap, FTSG	163	30	MSSA	Antibiotics, HBOT, NPWT	CDF/healed	3
15	59/M	MFH	Thigh	Wide resection	None	146	0	MSSA	Antibiotics, HBOT,	AWD/healed	1
16	73/F	Chondrosarcoma	Hand	Marginal resection including metatarsal bone	Iliac autograft, Kirschner wire	524	685	Enterobacter cloacae	Antibiotics, surgery (forearm flap)	CDF/healed	20
17	73/F	MFH	Thigh	Wide resection	Free latissimus dorsi flap, STSG	626	190	MRSA	Antibiotics, HBOT, surgery, NPWT	AWD/healed	3
18	68/F	Undifferentiated sarcoma	Thigh	Wide resection	STSG	189	30	MRSA	Antibiotics	CDF/healed	2

MFH: malignant fibrous histiocytoma (pleomorphic undifferentiated sarcoma); FTSG: full-thickness skin graft; STSG: split-thickness skin graft; MSSA: methicillin-sensitive Staphylococcus aureus; mRSA: Methicillin-resistant Staphylococcus aureus; CNS: coagulase-negative staphylococci; HBOT: hyperbaric oxygen therapy; NPWT: negative-pressure wound therapy; CDF: continuous disease free; DOD: died of disease; DOO: died of other cause (Case 8, uterine cervical cancer); AWD: alive with disease.